THE CLINICAL-APPLICATION OF 2 NEWLY DEVELOPED LIPID EMULSIONS (SOLIPID(R) 20-PERCENT S-AND-E) IN CRITICALLY ILL PATIENTS

Objective: The clinical compatibility of two newly developed lipid emu lsions based on soy oil (20%) emulsified with egg lecithin (12 g/l) or soy lecithin (15 g/l) (Solipid(R) 20% E & S) has been compared. Desig n: Double-blind prospective randomized study. Setting: Intensive care unit of a university hospital. Patients: 20 patients (16 men, 4 women, age 20-59 years) were entered into the study. interventions: One g of lipids/kg body weight per day was administered on day 1 and subsequen tly 2 g/kg/day on days 2-5. Blood was drawn once a day, lipids, lipopr oteins, apoproteins and other routine clinical chemistry parameters we re determined. Results: No significant increase of total triglycerides could be observed. Total cholesterol, low-density lipoprotein cholest erol, high-density lipoprotein cholesterol, apolipoproteins A I and B usually remained below the reference ranges. Electrolytes, uric acid a nd glucose, blood cells, parameters of liver and kidney function, coag ulation and protein metabolism did not show relevant changes; only the activity of gamma-GT in both groups - independent of the sort of leci thin - increased significantly. Conclusion: The results indicate adequ ate elimination of both tested lipid emulsions from the plasma at usua l clinical conditions. Therefore Solipid(R) 20% S gr E can be used in critically ill patients.